21 Pharmacists should also counsel patients on the importance of maintaining adequate hydration, especially in the presence of vomiting or diarrhea, to prevent dehydration and reduce the risk of acute kidney injury
Connor says
2013, 305 (2): E161-70
These include nausea, vomiting, diarrhoea, and constipation, typically occurring during treatment initiation or dose escalation
GHRP-2 Bottom line: GHRP-2 may be slightly more potent but comes with more hormonal disruption
While sommarutide is undoubtedly an exciting potential treatment option, there is still a lack of clear clinical data on the mechanism of action of GLP-1 agonists in NASH, such as whether GLP-1 agonists have a direct, independent role in improving NASH, or simply by improving body weight, insulin resistance, and so on